Basophil activation and serum IL‐5 levels as possible monitor biomarkers in severe eosinophilic asthma patients treated with anti‐IL‐5 drugs-Reference-Cited by-同舟云学术

Basophil activation and serum IL‐5 levels as possible monitor biomarkers in severe eosinophilic asthma patients treated with anti‐IL‐5 drugs

Published:2020-11-06 Issue:5 Volume:76 Page:1569-1571
ISSN:0105-4538
Container-title:Allergy
language:en
Short-container-title:Allergy

Author:

Caruso Cristiano¹^ORCID,Colantuono Stefania¹²,Tolusso Barbara³,Di Mario Clara⁴,Pentassuglia Antonella⁵,Rumi Gabriele¹,Gremese Elisa³⁴,Romano Antonino⁶⁷,Gasbarrini Antonio⁸

Affiliation:

1. Allergy Unit Fondazione Policlinico Universitario A. Gemelli IRCCS Rome Italy

2. Department of Translational and Precision Medicine Sapienza University Rome Italy

3. Division of Rheumatology Fondazione Policlinico Universitario A. Gemelli IRCCS Rome Italy

4. Division of Rheumatology Università Cattolica del Sacro Cuore Rome Italy

5. San Giovanni Battista Hospital Rome Italy

6. IRCCS Oasi Maria S.S. Troina Italy

7. Fondazione Mediterranea G.B. Morgagni Catania Italy

8. UOC Medicina Interna e GastroenterologiaFondazione Policlinico Universitario A. Gemelli IRCCSUniversità Cattolica del Sacro Cuore Rome Italy

Publisher

Wiley

Subject

Immunology,Immunology and Allergy

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/all.14643

Reference9 articles.

1. Anti‐IL‐5 therapies for asthma;Farne HA;Cochrane Database Syst Rev,2017

2. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial

3. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial

4. Toward clinically applicable biomarkers for asthma: An EAACI position paper

5. The importance of being not significant: Blood eosinophils and clinical responses do not correlate in severe asthma patients treated with mepolizumab in real life

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Switching from one biologic to benralizumab in patients with severe eosinophilic asthma: An ANANKE study post hoc analysis;Frontiers in Medicine;2022-09-02

2. The role of hypoxia in the pathophysiology of chronic rhinosinusitis;Allergy;2022-06-02

3. Heterogeneous Condition of Asthmatic Children Patients: A Narrative Review;Children;2022-03-01

4. Heterogeneous Response of Airway Eosinophilia to Anti-IL-5 Biologics in Severe Asthma Patients;Journal of Personalized Medicine;2022-01-07

5. Metabolomics, Microbiota, and In Vivo and In Vitro Biomarkers in Type 2 Severe Asthma: A Perspective Review;Metabolites;2021-09-22